Skip to content

Advertisement

Journal of Translational Medicine

Research
Open Access

Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts

  • Ruixia Huang1,
  • Lise Mari K. Andersen1 and
  • Einar K. Rofstad1, 2Email author
Journal of Translational Medicine201715:203

https://doi.org/10.1186/s12967-017-1307-4

©  The Author(s) 2017

Received: 28 March 2017

Accepted: 26 September 2017

Published: 10 October 2017

Abstract

Background

Malignant melanoma of the skin can metastasize through blood vessels and lymphatics. The primary tumor develops a vascular microenvironment characterized by abnormal blood vessels and lymphatics and a physicochemical microenvironment characterized by low oxygen tension, regions with hypoxic tissue, and high interstitial fluid pressure (IFP). This study aimed at identifying relationships between the metastatic route of melanomas and characteristic features of the microvascular and physicochemical microenvironments of the primary tumor.

Methods

Two patient-derived xenograft (PDX) models (E-13, N-15) and four cell line-derived xenografts (CDX) models (C-10, D-12, R-18, T-22) of human melanoma were included in the study. Tumors were transplanted to an orthotopic site in BALB/c-nu/nu mice, and when the tumors had grown to a volume of 500–600 mm3, the IFP of the primary tumor was measured and the hypoxia marker pimonidazole was administered before the host mouse was euthanized. The primary tumor, lungs, and six pairs of lymph nodes were evaluated by examining hematoxylin/eosin-stained and immunostained histological preparations. The expression of angiogenesis-related genes was assessed by quantitative PCR.

Results

C-10, D-12, and E-13 tumors disseminated primarily by the hematogenous route and developed pulmonary metastases. These tumors showed high angiogenic activity and high expression of the F3 gene as well as ANGPT2 and TIE1, genes encoding proteins of the angiopoietin–tie system. N-15, R-18, and T-22 tumors disseminated mainly by the lymphogenous route and developed metastases in draining lymph nodes. These tumors had highly elevated IFP and showed high expression of NRP2, a gene encoding neuropilin-2.

Conclusion

The primary metastatic route of orthotopic human melanoma xenografts and the development of lung and lymph node metastases are influenced significantly by the microvascular and physicochemical microenvironments of the primary tumor.

Keywords

Vascular tumor microenvironmentPhysicochemical tumor microenvironmentMelanomaMetastasisHemangiogenesisLymphangiogenesisMicrovasculatureInterstitial fluid pressureHypoxia

Background

Cutaneous melanoma is a highly aggressive disease of increasing incidence caused by malignant transformation of epidermal melanocytes [1, 2]. The disease progresses through distinct steps, and the transition from the radial growth phase to the vertical growth phase is associated with tumor-induced angiogenesis, increased metastatic propensity, and significant worsening of the prognosis [3, 4]. Primary melanomas in the vertical growth phase secret angiogenic factors that stimulate hem- and lymphangiogenesis, resulting in the development of a dense intratumoral network of blood vessels and an enriched peritumoral network of lymphatics [5–7]. High rates of hem- and lymphangiogenesis have been shown to be associated with metastatic growth and poor survival [8–13]. Recent reviews have concluded that the blood vessel density (BVD) in the tumor periphery and the peritumoral lymph vessel density (LVD) have significant prognostic power in patients with melanoma, whereas the BVD in central tumor regions and the intratumoral LVD may not have prognostic value [14–16].

Intravital microscopy studies have revealed that the blood vessel networks of melanomas in human patients show severe morphological abnormalities, including vessel disorganization, aberrant vessel bifurcations, heterogeneous vessel density, vessel tortuosity, increased vessel segment lengths, and highly permeable vessel walls [17]. These abnormalities cause irregular and heterogeneous blood flow, and may lead to the development of a physicochemical tumor microenvironment characterized by poor oxygenation and elevated interstitial fluid pressure (IFP) [18, 19]. Indeed, clinical investigations have revealed that low oxygen tension, hypoxic tumor regions, and high IFP are characteristic features of the physicochemical microenvironment of human melanomas [20–23].

Human melanoma xenografts are frequently being used as preclinical models of melanomas in patients, and it has been shown that the blood vessel and lymphatic networks of melanomas transplanted orthotopically to athymic nude mice are similar to those reported for human melanomas [24–26]. It has also been shown that orthotopic melanoma xenografts develop hypoxic regions and elevated IFP [27, 28], and furthermore, that metastatic dissemination and growth is associated with high angiogenic activity, extensive hypoxia, and high IFP in the primary tumor [29–31]. These findings have led to the suggestion that there is a link between the angiogenic signature, vascular morphology and function, and the physicochemical microenvironment in melanomas, and that interactions between these biological features may lead to a hostile tumor microenvironment promoting metastasis to regional lymph nodes and distant organs [32].

Cutaneous melanoma disseminates through blood vessels and lymphatics, and can show an organ specific metastatic pattern [33]. The time course to the development of distant metastases may differ between the metastatic pathways [34], and the progression of melanomas spreading by the hematogenous route is believed to be fast compared with that of melanomas spreading by the lymphogenous route [33–35]. Several genetic biomarkers associated with the metastatic route and organ specific metastasis have been identified [33]. However, studies examining the possibility that the metastatic pathway of melanomas is influenced significantly by the vascular and physicochemical tumor microenvironments are sparse.

In a previous study, we searched for associations between the overall metastatic propensity, the angiogenic potential, and the hypoxic tumor microenvironment of melanomas by using nine different melanoma xenograft lines as preclinical tumor models [36]. The study revealed that the metastatic propensity was determined by the tumor microvascular density rather than the fraction of hypoxic tissue, and vascular endothelial growth factor-A and interleukin-8 were identified as important drivers of tumor angiogenesis. In the study reported here, we addressed the possibility that the metastatic pathway and organ specific metastatic pattern of melanomas is influenced by the microvascular and physicochemical tumor microenvironments by searching for associations between metastatic spread and BVD, LVD, IFP, fraction of hypoxic tissue, and angiogenic signature. Orthotopic patient derived xenograft (PDX) models and cell line-derived xenograft (CDX) models of cutaneous melanoma were examined, and we provide significant evidence that tumor angiogenesis and the physicochemical tumor microenvironment may have strong impact on the metastatic pathway of melanomas.

Methods

Tumor models

Adult (8–12 weeks of age) female BALB/c nu/nu mice, bred and maintained at our research institute [32], were used as host animals for xenografted tumors. Four CDX models (C-10, D-12, R-18, T-22) and two PDX models (E-13, N-15) of metastatic melanoma were included in the study. The CDX models and the patients from whom permanent cell lines were established in culture have been described elsewhere [36]. The E-13 PDX model was obtained from a lymph node metastasis in the axilla of a 52-year-old female melanoma patient. The donor developed multiple pulmonary metastases and died from metastatic growth in the brain 18 months after presentation at the Norwegian Radium Hospital. The N-15 PDX model was derived from a lymph node metastasis in the abdomen of a 60-year-old male admitted to the Norwegian Radium Hospital for the treatment of metastatic melanoma. The donor patient responded poorly to chemotherapy and died from metastatic growth in the liver 27 months after the initiation of treatment. Both PDX models were established in BALB/c nu/nu mice by implanting small tumor pieces subcutaneously, and they have been maintained solely in vivo by serial subcutaneous transplantation of tumor cell aliquots. In the present study, we used orthotopic tumors initiated by intradermal inoculation of aliquots of ~ 3.5 × 105 to ~ 1.0 × 106 cells suspended in 10 μl of Hanks’ balanced salt solution. Tumors were included in experiments when having grown to a volume of 500–600 mm3. The volume (V) and the volume doubling time (T d) of the tumors were calculated as V = π/6 × a × b × c and T d = ln2 × t/(lnV t − lnV 0), where a, b, and c are three orthogonal tumor diameters measured with calipers, and V t and V 0 are tumor volume at time t and time zero, respectively.

Tumor interstitial fluid pressure

Tumor-bearing mice were anesthetized with fluanisone (20 mg/kg body weight), midazolam (10 mg/kg body weight), and fentanyl citrate (0.63 mg/kg body weight), and IFP was measured in the tumor center with a Millar SPC 320 catheter equipped with a 2F Mikro-Tip transducer (Millar Instruments, Houston, TX, USA) [28]. The catheter was connected to a computer, and data were acquired with the LabVIEW software. Two independent measurements were carried out in each tumor by inserting the IFP probe from two opposite directions, and these measurements provided highly similar IFP values.

Immunohistochemical assessment of tumor hypoxic fraction, vessel density, and protein levels

Pimonidazole [1-[(2-hydroxy-3-piperidinyl)-propyl]-2-nitroimidazole], a marker of tumor hypoxia, was administered to the mice in a dose of 30 mg/kg body weight immediately after tumor IFP was measured. The mice were euthanized 3–4 h later, and the primary tumor was removed for immunohistochemical assessment of hypoxic fraction (HFPim), vascular density, and the levels of angiopoietin-2, coagulation factor-III, tie1, and neuropilin-2. CD31 and LYVE-1 were used as markers of blood and lymph vessel endothelial cells, respectively. Histological sections were prepared by standard procedures, and immunostaining was carried out by using a peroxidase-based indirect staining method [29]. An anti-pimonidazole rabbit polyclonal antibody (provided by Professor Raleigh, University of North Carolina, Chapel Hill, NC, USA), an anti-mouse CD31 rabbit polyclonal antibody (Abcam, Cambridge, UK), an anti-mouse LYVE-1 rabbit polyclonal antibody (Abcam), an anti-human angiopoietin-2 rabbit polyclonal antibody (Abcam), an anti-human coagulation factor-III rabbit polyclonal antibody (Abcam), an anti-human tie1 rabbit polyclonal antibody (Abcam), or an anti-human neuropilin-2 rabbit polyclonal antibody (Abcam) was used as primary antibody. Diaminobenzidine was used as chromogen, and hematoxylin was used for counterstaining. Quantitative studies were carried out on preparations cut through the central regions of tumors and the surrounding tissue, and three sections of each staining were analyzed for each tumor. Staining densities were quantified by using the ImageJ software. Microvessels were defined and scored manually as described by Weidner [15]. Blood vessel density (BVD) in the invasive front (peripheral BVD) was assessed by counting vessels located within a 1-mm-thick band in the tumor periphery [32]. Peritumoral lymph vessel density (LVD) was determined by counting vessels in the surrounding skin located within a distance of 0.5 mm from the tumor surface [32]. HFPim was assessed by image analysis and was defined as the area fraction of the non-necrotic tissue showing positive pimonidazole staining [27].

Tumor metastasis

The lungs and six pairs of lymph nodes (i.e., popliteal lymph nodes, inguinal lymph nodes, proper axillary lymph nodes, accessory axillary lymph nodes, medial iliac lymph nodes, and renal lymph nodes) were resected and examined for metastatic growth by light microscopy. Histological sections were cut at 100-μm intervals throughout the resected tissue and stained with hematoxylin and eosin. A group of five or more melanoma cells was scored as metastatic growth. Usually, the metastatic deposits had grown to a diameter of more than 100 μm when the lungs and lymph nodes were resected.

Quantitative PCR (qPCR)

The RT2 Profiler PCR Array Human Angiogenesis (PAHS-024Z; SABiosciences, Frederick, MD, USA) was used for expression profiling of angiogenesis-related genes. The genes included in the array are presented in Additional file 1: Table S1. Total RNA was isolated from tumor tissue stabilized in RNAlater RNA Stabilization Reagent (Qiagen, Hilden, Germany). RNA isolation, cDNA synthesis, and real-time qPCR were carried out as described earlier [26]. Fold difference in gene expression was calculated by using the ∆∆CT-method [37]. A CT-value of 35 (15 cycles above the positive PCR control) was set as detection limit, and consequently, genes with CT-values above 35 were not included in the analysis. The arrays included five house-keeping genes [β-actin (ACTB), β-2-microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase-1 (HPRT1), ribosomal protein lateral stalk subunit P0 (RPLP0)], and each CT-value of a tumor was normalized to the mean CT-value of these genes (∆CT = C T gene of interest  − C T mean of housekeeping genes ). Normalized gene expression levels were calculated from three tumors as \(2^{{ - \,{\text{mean}}\;\Delta {\text{C}}_{\text{T}} }}\).

Statistical analysis

Statistical analysis was carried out with the SigmaStat statistical software. Data are shown as mean ± standard error unless otherwise stated. The Kolmogorov–Smirnov method and the Levene’s method were used to test for normality and equal variance. Comparisons of data were carried out by using the Student t test (single comparisons) or by one-way ANOVA followed by the Bonferroni’s test (multiple comparisons) when the data complied with the conditions of normality and equal variance. Under other conditions, comparisons were carried out by non-parametric analysis using the Mann–Whitney rank-sum test (single comparisons) or by Kruskal–Wallis ANOVA on ranks followed by the Dunn’s test (multiple comparisons). Probability values of p < 0.05, determined from two-sided tests, were considered significant.

Results

The melanoma models showed different primary metastatic routes

Metastatic frequency was determined by studying a total of fifty tumor-bearing mice of each melanoma model. Four experiments were carried out, each involving 10–15 mice per model, and metastatic growth was observed frequently, both in lymph nodes (Fig. 1a) and lungs (Fig. 1b). The incidence metastasis (i.e., the percentage of mice that showed metastatic growth) and the metastatic pattern differed significantly among the six melanoma models, whereas the number of metastatic lesions in each metastasis-positive mouse did not. The N-15, R-18, and T-22 models showed higher incidence of lymph node metastasis than the C-10, D-12, and E-13 models (p = 0.016; Fig. 1c), whereas the incidence of pulmonary metastasis was higher in the C-10, D-12, and E-13 models than in the N-15, R-18, and T-22 models (p = 0.0012; Fig. 1d). Lymph node metastases develop primarily from tumor cells disseminated through lymphatics associated with the primary tumor, whereas the development of pulmonary metastases can be a result of tumor cell dissemination through primary tumor-associated blood vessels as well as tumor cell dissemination from lymph node metastases [6, 14, 16]. The incidence of lymph node metastasis was higher than the incidence of pulmonary metastases in the N-15, R-18, and T-22 models (p = 0.00075), and consequently, N-15, R-18, and T-22 tumors disseminated primarily through the lymphogenous route. The incidence of pulmonary metastasis was higher than the incidence of lymph node metastasis in the C-10, D-12, and E-13 models (p = 0.022), and consequently, indicative that the hematogenous route was the primary metastatic route in these tumors.
Fig. 1

The metastatic pattern of six human melanoma xenograft models. Histological preparations showing metastatic growth in lymph node (a) and lung (b). C-10, D-12, and E-13 tumors showed lower incidence of lymph node metastasis (c) and higher incidence of pulmonary metastasis (d) than N-15, R-18, and T-22 tumors. The percentage of mice that showed metastatic growth was used as a parameter for incidence of metastasis. Columns and bars: mean values ± standard error of four experiments, each involving 10–15 mice per melanoma model. The experiments were carried out by using adult (8–12 weeks of age) female BALB/c nu/nu mice as host animals

The metastatic route differed with the physicochemical tumor microenvironment

IFP was measured in all primary tumors (i.e., 50 tumors per melanoma model), whereas 20 tumors of each model were selected randomly for immunostaining and assessment of HFPim, BVD, and LVD. The N-15, R-18, and T-22 models showed higher IFP than the C-10, D-12, and E-13 models (p = 0.0011; Fig. 2a), suggesting an association between lymphogenous metastasis and highly elevated tumor IFP. HFPim did not differ between the C-10, D-12, and E-13 models on the one hand and the N-15, R-18, and T-22 models on the other, as illustrated qualitatively by using a C-10 and a T-22 tumor as representative examples (Additional file 2: Figure S1a) and shown quantitatively by presenting HFPim data for all six models (p > 0.05; Fig. 2b). This observation suggests that the primary metastatic route was not determined by the extent of tumor hypoxia.
Fig. 2

Tumor interstitial fluid pressure (IFP) and fraction of hypoxic tissue (HFPim) in two groups of human melanoma xenografts differing in metastatic pattern. N-15, R-18, and T-22 tumors showed higher IFP than C-10, D-12, and E-13 tumors (a), but did not differ from C-10, D-12, and E-13 tumors in HFPim (b). Columns and bars: mean values ± standard error (n = 50 in a and n = 20 in b, where n represents the number of examined tumors). The experiments were carried out by using adult (8–12 weeks of age) female BALB/c nu/nu mice as host animals

The metastatic route was linked to tumor angiogenic activity

The C-10, D-12, and E-13 models did not differ from the N-15, R-18, and T-22 models in peripheral tumor BVD or peritumoral LVD. This is illustrated qualitatively in Additional file 2: Figure S1b, c, which show representative examples of histological preparations immunostained for blood vessels and lymphatics, and quantitatively in Fig. 3a (p > 0.05) and Fig. 3b (p > 0.05). However, C-10, D-12, and E-13 tumors grew faster (p < 0.0001; Fig. 3c) and, hence, had shorter T d (p = 0.0022; Fig. 3d) than N-15, R-18, and T-22 tumors. The rate of induction of new blood vessels (i.e., the angiogenic activity) is different in experimental tumors that show the same microvascular density but have different growth rates [38]. Because C-10, D-12, and E-13 tumors grew faster than N-15, R-18, and T-22 tumors and these two tumor groups had similar peripheral BVD and peritumoral LVD, the C-10, D-12, and E-13 models induced higher angiogenic activity than the N-15, R-18, and T-22 models. From these data and the data reported in Fig. 1, it follows that hematogenous metastatic dissemination and the development of pulmonary metastases were associated with high angiogenic activity in the primary tumor.
Fig. 3

Peripheral blood vessel density (BVD), peritumoral lymph vessel density (LVD), tumor growth curves, and tumor volume doubling time (T d) of two groups of human melanoma xenografts differing in metastatic pattern. C-10, D-12, and E-13 tumors did not differ from N-15, R-18, and T-22 tumors in peripheral BVD (a) or peritumoral LVD (b), but grew faster (c) and, hence, had shorter T d than N-15, R-18, and T-22 tumors (d). Columns and bars: mean values ± standard error (n = 20 in a, b and n = 50 in d, where n represents the number of studied tumors). Symbols and bars in c: Geometric mean ± standard error (n = 50). The experiments were carried out by using adult (8–12 weeks of age) female BALB/c nu/nu mice as host animals

The metastatic route was linked to tumor angiogenic signature

In general, more angiogenesis-related genes showed high expression in the C-10, D12, and E-13 models than in the N-15, R-18, and T-22 models (Fig. 4a). Three genes showed more than twofold higher expression in C-10, D-12, and E-13 tumors than in N-15, R-18, and T-22 tumors: ANGPT2 (angiopoietin-2), F3 (coagulation factor-III), and TIE1 (tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains-1), whereas NRP2 (neuropilin-2) was the only gene that showed more than twofold higher expression in N-15, R-18, and T-22 tumors than in C-10, D-12, and E-13 tumors (Fig. 4b).
Fig. 4

Expression of angiogenesis-related genes in two groups of human melanoma xenografts differing in metastatic pattern. A PCR array with 84 genes was used for expression profiling, and the genes on the array are presented in Additional file 1: Table S1. a Expression level in C-10, D-12, and E-13 tumors vs expression level in N-15, R-18, and T-22 tumors. Points: mean values of single genes determined from three different tumors. Solid lines: twofold difference in expression level. b Mean expression level of ANGPT2, F3, NRP2, and TIE1 in C-10, D-12, and E-13 tumors divided by that in N-15, R-18, and T-22 tumors. The mean expression of ANGPT2, F3, and TIE1 was more than twofold higher in C-10, D-12, and E-13 tumors than in N-15, R-18, and T-22 tumors [statistical analysis revealed that all 27 ratios were higher than 2 (p < 0.01)], whereas the mean expression of NRP2 was more than twofold higher in N-15, R-18, and T-22 tumors than in C-10, D-12, and E-13 tumors [statistical analysis revealed that all 9 ratios were lower than 0.5 (p < 0.005)]. The tumors were grown in adult (8–12 weeks of age) female BALB/c nu/nu mice

The protein levels of these genes were investigated by subjecting primary tumors and their metastases to immunohistochemistry. The immunohistochemistry data were fully in agreement with the qPCR data. The C-10, D-12, and E-13 models showed higher protein levels of the ANGPT2, F3, and TIE1 genes than the N-15, R-18, and T-22 models, whereas the NRP2 protein level was higher in the N-15, R-18, and T-22 models than in the C-10, D-12, and E-13 models, as illustrated in Fig. 5 by using a C-10 and a T-22 tumor as representative examples. Five tumors of each model were subjected to quantitative analysis, which revealed that the staining density of C-10, D-12, and E-13 tumors was higher than that of N-15, R-18, and T-22 tumors for angiopoietin-2 (p = 0.0028), coagulation factor III (p = 0.0091), and tie1 (p = 0.0032) and lower than that of N-15, R-18, and T-22 tumors for neuropilin-2 (p = 0.0056), as illustrated in Fig. 5. Thus, hematogenous metastatic spread and the development of pulmonary metastases were associated with high expression of ANGPT2, F3, and TIE1, whereas lymphogenous metastatic spread and the development of lymph node metastases were associated with high expression of NRP2.
Fig. 5

Immunohistochemical preparations. Images and staining densities of histological preparations immunostained for angiopoietin-2 (a), coagulation factor-III (b), tie1 (c), and neuropilin-2 (d). The images show representative examples, refer to a primary tumor of the C-10 melanoma xenograft model and a primary tumor of the T-22 melanoma xenograft model, and illustrate that C-10 tumors showed higher expression of angiopoietin-2, coagulation factor-III, and tie1 and lower expression of neuropilin-2 than T-22 tumors. Staining densities were for each protein normalized to the mean value of the tumor model that showed the highest staining density. C-10, D-12, and E-13 tumors showed higher staining density for angiopoietin-2, coagulation factor-III, and tie1 and lower staining density for neuropilin-2 than N-15, R-18, and T-22 tumors. Columns and bars: mean values ± standard error (n = 5, where n represents the number of studied tumors). The tumors were grown in adult (8–12 weeks of age) female BALB/c nu/nu mice

Discussion

Hematogenous and lymphogenous metastatic spread are characteristic features of angiogenic human melanomas [33, 34], and the possibility that the metastatic route is associated with the microvascular and physicochemical microenvironments of the primary tumor was investigated in this study by using orthotopic melanoma xenografts as preclinical models of human disease. C-10, D-12, and E-13 tumors disseminated primarily by the hematogenous route and developed pulmonary metastases, whereas N-15, R-18, and T-22 tumors mainly showed lymphogenous metastatic spread. These two tumor groups did not differ significantly in HFPim, peripheral BVD, or peritumoral LVD, suggesting that tumor hypoxia and microvascular density are not important determinants of the primary metastatic route of melanomas.

Because the peripheral BVD of C-10, D-12, and E-13 tumors was similar to that of N-15, R-18, and T-22 tumors and C-10, D-12, and E-13 tumors grew faster and showed higher expression of angiogenesis-related genes than N-15, R-18, and T-22 tumors, the angiogenic activity was higher in C-10, D-12, and E-13 tumors than in N-15, R-18, and T-22 tumors. Consequently, hematogenous metastatic spread of melanomas may be associated with high angiogenic activity in the primary tumor. This suggestion is in accordance with clinical studies having shown higher angiogenic activity in the primary tumor in melanoma patients with distant organ metastases than in those with lymph node metastases only [39]. High angiogenic activity may promote hematogenous metastasis of tumors by several mechanisms. First, fast formation of new blood vessels leads to the development of an immature microvasculature with fragmented basement membrane, leaky vessels, and high density of vessel sprouts, morphological characteristics that may facilitate tumor cell intravasation [40]. Furthermore, elevated capacity to induce neovascularization may increase the probability of tumor cells trapped in secondary organ capillary beds to extravasate and give rise to macroscopic growth [41].

IFP was substantially higher in N-15, R-18, and T-22 tumors than in C-10, D-12, and R-18 tumors, suggesting that lymphogenous metastatic spread of melanomas is associated with highly elevated IFP in the central regions of the primary tumor. High IFP has been shown to promote lymph node metastasis also in human cervix carcinoma and pancreatic carcinoma xenografts [42, 43]. Mechanisms linking high IFP in tumors to lymph node metastasis have not been identified conclusively, but several possible mechanisms have been suggested. First, high tumor IFP may force interstitial fluid to flow from the tumor tissue into adjacent normal tissues [42], and this fluid flow may direct tumor cells toward peritumoral lymphatics by autologous chemotaxis [44]. Moreover, the interstitial fluid may transport proteolytic enzymes and chemokines that facilitate tumor cell migration by remodeling the extracellular matrix [44], and may carry lymphangiogenic factors that promote metastasis by dilating peritumoral lymphatics and inducing lymphangiogenesis [45].

Tumors develop elevated IFP because they show high resistance to blood flow, low resistance to transcapillary fluid flow, and impaired lymphatic drainage, and the intertumor heterogeneity in IFP is primarily a consequence of differences in blood flow resistance [46]. Low-diameter vessels are the main cause of high resistance to blood flow, but abnormal vessel bifurcations, vessel tortuosity, and long vessel segment lengths may also contribute significantly [47]. The resistance to blood flow was most likely higher in N-13, R-18, and T-22 tumors than in C-10, D-12, and E-13 tumors, resulting in higher IFP in the former group of tumors. Taken together, our observations suggest that melanomas disseminating primarily by the lymphogenous route develop a microvascular network that exerts high resistance to blood flow and causes highly elevated IFP, whereas melanomas disseminating primarily by the hematogenous route have highly elevated angiogenic activity that results in a microvascular network with dilated vessels that exerts lower resistance to blood flow and facilitates tumor cell intravasation.

The expression of ANGPT2, F3, and TIE1 was more than twofold higher in C-10, D-12, and E-13 tumors than in N-15, R-18, and T-22 tumors, and the expression of NRP2 was more than twofold higher in N-15, R-18, and T-22 tumors than in C-10, D-12, and E-13 tumors. These observations suggest that high expression of F3 and genes of the angiopoietin–tie system is associated with high angiogenic activity, hematogenous metastatic spread, and the development of pulmonary metastases in melanoma xenografts, whereas high expression of NRP2 is associated with lymphogenous metastatic spread and the development of lymph node metastases. Further studies are needed to ascertain whether there is a causal relationship between elevated expression of these genes and the metastatic route of melanomas.

The angiopoietin–tie system plays important roles in vascular development, morphogenesis, and homeostasis, and is implicated in several diseases where the vasculature is important, including cancer [48, 49]. Blocking of ANGPT2 protein or genetic deletion of TIE1 has been shown to decrease tumor angiogenesis and growth by reducing endothelial cell sprouting and by inducing endothelial cell apoptosis and vessel regression [50, 51]. It has also been revealed that blocking of ANGPT2 protein may induce vascular normalization in tumors [52], inhibit transendothelial migration of tumor cells [53], and decrease pulmonary metastasis and growth of experimental tumors [54–56]. The association between hematogenous metastatic spread of melanomas and high expression of ANGPT2 and TIE1 reported here is consistent with these observations.

F3 encodes coagulation factor III, also known as tissue factor (TF). Full length TF promotes tumor angiogenesis by up-regulating the expression of several proangiogenic factors, including interleukin-8, chemokine (C-X-C motif) ligand-1, and vascular endothelial growth factor-A [57, 58]. Spliced TF may stimulate tumor angiogenesis through protein tyrosine kinase-2 signaling by ligating to endothelial cell integrins such as αvβ3 and α6β1 [57, 59]. In addition, TF may play an important role in tumor cell intravasation [60]. The significance of TF in lung metastasis of melanoma has been studied previously [61, 62]. TF was found to promote lung colonization of melanoma cells inoculated intravenously into immunodeficient mice, but did not facilitate spontaneous lung metastasis of subcutaneous melanomas. It is thus possible that the association between pulmonary metastasis and high expression of F3 reported here was due to effects of TF in the later phases of the metastatic process after the melanoma cells had entered the blood circulation as well as effects of TF within the primary tumor.

NRP2 encodes the neuropilin-2 protein, which is a transmembrane multifunctional nonkinase receptor for class III semaphorins, members of the vascular endothelial growth factor family, and other growth factors [63]. Tumor-induced activation of neuropilin-2 on lymphatic endothelial cells can increase peritumoral lymphangiogenesis and promote lymph node metastasis [64]. Neuropilin-2 on tumor cells interacts with integrins on blood and lymph vessel endothelial cells to mediate vascular adhesion and promote extravasation [65]. High expression of NRP2 has been shown to promote hematogenous metastatic spread in pancreatic adenocarcinoma and clear cell renal cell carcinoma xenografts [65] and the development of lymph node metastases in patients with breast carcinoma [66], papillary thyroid carcinoma [67], and squamous cell carcinoma of the oesophagus [68]. Immunohistochemical investigations have revealed that melanomas show high expression of neuropilin-2 and that the expression is higher in lymph node metastases than in the primary tumor [69]. These observations suggest that the association between high expression of NRP2 and lymph node metastasis reported here was not due to effects of neuropilin-2 within the primary tumor, but most likely was due to interaction between melanoma cells and lymphatic endothelial cells after the melanoma cells had entered the peritumoral lymphatic network.

Conclusions

Orthotopic melanoma xenografts can metastasize by the hematogenous and the lymphogenous pathway. Melanomas that disseminate primarily through the hematogenous route show high angiogenic activity in the primary tumor, high incidence of pulmonary metastases, and high expression of the F3 gene as well as genes encoding central proteins of the angiopoietin–tie system. Melanomas that spread primarily through the lymphogenous route are characterized by highly elevated IFP in the primary tumor and metastatic growth in draining lymph nodes. High IFP is mainly a consequence of high resistance to blood flow, and metastatic growth in lymph nodes is most likely facilitated by high expression of NRP2.

Abbreviations

ACTB: 

β-actin

ANGPT2: 

angiopoietin-2

B2M: 

β-2-microglobulin

BVD: 

blood vessel density

CDX models: 

cell line-derived xenograft models

F3: 

coagulation factor-III

GAPDH: 

glyceraldehyde-3-phosphate dehydrogenase

HFPim : 

hypoxic fraction assessed with pimonidazole as hypoxia marker

HPRT1: 

hypoxanthine phosphoribosyltransferase-1

IFP: 

interstitial fluid pressure

LVD: 

lymph vessel density

NRP2: 

neuropilin-2

PDX models: 

patient-derived xeno-graft models

qPCR: 

quantitative polymerase chain reaction

RPLP0: 

ribosomal protein lateral stalk subunit P0

T d : 

tumor volume doubling time

TF: 

tissue factor

TIE1: 

tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains-1

Declarations

Authors’ contributions

RH, LMKA, EKR developed the original hypothesis and experimental design. RH, LMKA carried out experiments. RH, EKR analyzed data. RH, EKR wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The materials used and the datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The animal experiments were approved by the Norwegian National Animal Research Authority (Approval Number: FOTS-2751) and were conducted in accordance with the Interdisciplinary Principles and Guidelines for the use of Animals in Research, Marketing, and Education (New York Academy of Sciences, New York, NY, USA). The use of human tissue for establishing CDX and PDX models of human melanoma was approved by our institution (Committee for Medical and Health Research Ethics).

Funding

Financial support was received from the Norwegian Cancer Society and the South-Eastern Norway Regional Health Authority. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Group of Radiation Biology and Tumor Physiology, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
(2)
Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo, Norway

References

  1. Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. Eur J Cancer. 2013;11(Suppl II):81–91.View ArticleGoogle Scholar
  2. Wick MR. Cutaneous melanoma: a current overview. Semin Diagn Pathol. 2016;33:225–41.View ArticlePubMedGoogle Scholar
  3. Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia-Ramirez M, Fabra A. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol. 1997;24:212–8.View ArticlePubMedGoogle Scholar
  4. Laga AC, Murphy GF. Cellular heterogeneity in vertical growth phase melanoma. Arch Pathol Lab Med. 2010;134:1750–7.PubMedGoogle Scholar
  5. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 1997;7(Suppl 2):S19–26.PubMedGoogle Scholar
  6. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003;22:3172–9.View ArticlePubMedGoogle Scholar
  7. Ribatti D, Annese T, Longo V. Angiogenesis and melanoma. Cancers (Basel). 2010;2:114–32.View ArticleGoogle Scholar
  8. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol. 1988;133:419–23.PubMedPubMed CentralGoogle Scholar
  9. Srivastava A, Hughes LE, Woodcock JP, Laidler P. Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour. Br J Cancer. 1989;59:89–91.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162:1951–60.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Ribatti D, Nico B, Floris C, Mangieri D, Piras F, Ennas MG, Vacca A, Sirigu P. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep. 2005;14:81–4.PubMedGoogle Scholar
  12. Toberer F, Werchau S, Christia E, Enk A, Schirmacher P, Helmbold P. Large lymphatic vessel density in primary malignant melanoma predicts sentinel node status. J Am Acad Dermatol. 2013;69:827–8.View ArticlePubMedGoogle Scholar
  13. Spiric Z, Eric M, Eri Z, Skrobic M. Significantly high lymphatic vessel density in cutaneous metastasizing melanoma. Hippokratia. 2015;19:210–5.PubMedPubMed CentralGoogle Scholar
  14. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008;216:347–54.View ArticlePubMedGoogle Scholar
  15. Weidner N. Measuring intratumoral microvessel density. Methods Enzymol. 2008;444:305–23.View ArticlePubMedGoogle Scholar
  16. Pastushenko I, Vermeulen PB, Carapeto FJ, van den Eynden G, Rutten A, Ara M, Dirix LY, van Laere S. Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. Br J Dermatol. 2014;170:66–77.View ArticlePubMedGoogle Scholar
  17. Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016;7:10684.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in preclinical models. Microcirculation. 2010;17:206–25.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment. Front Oncol. 2016;6:66.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991;51:6691–4.PubMedGoogle Scholar
  21. Curti BD, Urba WJ, Alvord WG, Janik JE, Smih JW, Madara K, Longo DL. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993;53:2204–7.PubMedGoogle Scholar
  22. Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Eschwege F, Guichard M. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res. 1997;7:400–6.View ArticlePubMedGoogle Scholar
  23. Hartman P, Mirtolouei R, Untersberger S, Ziegler W, Hermann Z, Richtig E, Hofmann-Wellenhof R, Grinschgl S, Kerl H, Smolle J. Non-invasive imaging of tissue pO2 in malignant melanoma of the skin. Melanoma Res. 2006;16:479–86.View ArticleGoogle Scholar
  24. Brurberg KG, Gaustad JV, Mollatt CS, Rofstad EK. Temporal heterogeneity in blood supply in human tumor xenografts. Neoplasia. 2008;10:727–35.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK. A novel application of dorsal window chambers: repetitive imaging of tumor-associated lymphatics. Microvasc Res. 2012;83:360–5.View ArticlePubMedGoogle Scholar
  26. Simonsen TG, Gaustad JV, Leinaas MN, Rofstad EK. Tumor-line specific causes of intertumor heterogeneity in blood supply in human melanoma xenografts. Microvasc Res. 2013;85:16–23.View ArticlePubMedGoogle Scholar
  27. Rofstad EK, Galappathi K, Mathiesen B, Ruud EBM. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res. 2007;13:1971–8.View ArticlePubMedGoogle Scholar
  28. Rofstad EK, Ruud EBM, Mathiesen B, Galappathi K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res. 2010;16:936–45.View ArticlePubMedGoogle Scholar
  29. Rofstad EK, Halsør EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 2000;60:4932–8.PubMedGoogle Scholar
  30. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 2002;62:1847–53.PubMedGoogle Scholar
  31. Rofstad EK, Tunheim SH, Mathiesen B, Graff BA, Halsør EF, Nilsen K, Galappathi K. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 2002;62:661–4.PubMedGoogle Scholar
  32. Rofstad EK, Galappathi K, Mathiesen BS. Tumor interstitial fluid pressure—a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia. 2014;7:586–94.View ArticleGoogle Scholar
  33. Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ. Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res. 2016;30:13–27.View ArticlePubMedGoogle Scholar
  34. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70.View ArticlePubMedGoogle Scholar
  35. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572–6.PubMedPubMed CentralGoogle Scholar
  36. Rofstad EK, Mathiesen B. Metastasis in melanoma xenografts is associated with tumor microvascular density rather than extent of hypoxia. Neoplasia. 2010;12:889–98.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Vanguilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44:619–26.View ArticlePubMedGoogle Scholar
  38. Graff BA, Bjørnæs I, Rofstad EK. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res. 2001;61:187–98.View ArticlePubMedGoogle Scholar
  39. Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol. 1999;6:70–4.View ArticlePubMedGoogle Scholar
  40. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796:293–308.PubMedGoogle Scholar
  41. Zetter BR. Angiogenesis and tumor metastasis. Ann Rev Med. 1998;49:407–24.View ArticlePubMedGoogle Scholar
  42. Hompland T, Ellingsen C, Øvrebø KM, Rofstad EK. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI. Cancer Res. 2012;72:4899–908.View ArticlePubMedGoogle Scholar
  43. Andersen LMK, Wegner CS, Simonsen TG, Huang R, Gaustad JV, Hauge A, Galappathi K, Rofstad EK. Lymph node metastasis and the physicochemical microenvironment of pancreatic ductal adenocarcinoma xenografts. Oncotarget. 2017;8:48060–74.Google Scholar
  44. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell. 2007;11:526–38.View ArticlePubMedGoogle Scholar
  45. Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009;13:1405–16.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys. 1999;43:1111–23.View ArticlePubMedGoogle Scholar
  47. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988;48:2641–58.PubMedGoogle Scholar
  48. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165–77.View ArticlePubMedGoogle Scholar
  49. Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. Clin Sci. 2016;131:87–103.View ArticlePubMed CentralGoogle Scholar
  50. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70:2213–23.View ArticlePubMedPubMed CentralGoogle Scholar
  51. D’Amico G, Korhonen EA, Anisimov A, Zarkada G, Holopainen T, Hagerling R, Kiefer F, Eklund L, Sormunen R, Elamaa H, Brekken RA, Adams RH, Koh GY, Saharinen P, Alitalo K. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J Clin Investig. 2014;124:824–34.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM. Contrasting actions of selective inhibitors of angiopoietin-1 and angio-poietin-2 on the normalization of tumor blood vessels. Am J Pathol. 2009;175:2159–70.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P. Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat Commun. 2015;6:5962.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, de Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19:512–26.View ArticlePubMedGoogle Scholar
  55. Holopainen T, Saharinen P, D’Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Helotera H, Tammela T, Benjamin LE, Ylä-Herttuala S, Leow CC, Koh GY, Alitalo K. Effects of angiopoietin-2-blocking antibody on endothelial cell–cell junctions and lung metastasis. J Natl Cancer Inst. 2012;104:461–75.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, Augustin HG. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014;26:880–95.View ArticlePubMedGoogle Scholar
  57. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924–32.View ArticlePubMedGoogle Scholar
  58. Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res. 2010;125(Suppl 2):S36–8.View ArticlePubMedGoogle Scholar
  59. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA. 2009;106:19497–502.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Conn EM, Madsen MA, Cravatt BF, Ruf W, Deryugina EI, Quigley JP. Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation. J Biol Chem. 2008;283:26518–27.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA. 1992;89:11832–6.View ArticlePubMedPubMed CentralGoogle Scholar
  62. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA. 1995;92:8205–9.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol. 2007;212:237–48.View ArticlePubMedGoogle Scholar
  64. Wang J, Huang Y, Zhang J, Wei Y, Mahoud S, Bakheet AM, Wang L, Zhou S, Tang J. Pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis. Clin Chim Acta. 2016;461:165–71.View ArticlePubMedGoogle Scholar
  65. Cao Y, Hoeppner LH, Bach S, Guangqi E, Guo Y, Wang E, Wu J, Cowley MJ, Chang DK, Waddell N, Grimmond SM, Biankin AV, Daly RJ, Zhang X, Mukhopadhyay D. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin. Cancer Res. 2013;73:4579–90.View ArticlePubMedPubMed CentralGoogle Scholar
  66. Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T, Nakamura Y. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer. 2009;9:220.View ArticlePubMedPubMed CentralGoogle Scholar
  67. Yasuoka H, Kodama R, Hirokawa M, Takamura Y, Miyauchi A, Inagaki M, Sanke T, Nakamura Y. Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype. J Clin Endocrinol Metab. 2011;96:E1857–61.View ArticlePubMedGoogle Scholar
  68. Fung TM, Ng KY, Tong M, Chen JN, Chai S, Chan KT, Law S, Lee NP, Choi MY, Li B, Cheung AL, Tsao SW, Qin YR, Guan XY, Chan KW, Ma S. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. J Pathol. 2016;239:309–19.View ArticlePubMedGoogle Scholar
  69. Rushing EC, Stine MJ, Hahn SJ, Shea S, Eller MS, Naif A, Khanna S, Westra WH, Jungbluth AA, Busam KJ, Mahalingam M, Alani RM. Neuropilin-2: a novel biomarker for malignant melanoma? Hum Pathol. 2012;43:381–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us